Ocugen (OCGN) Competitors $0.71 +0.08 (+12.13%) Closing price 03/25/2025 04:00 PM EasternExtended Trading$0.73 +0.02 (+2.42%) As of 03/25/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock OCGN vs. LENZ, MRVI, DNTH, CRMD, ORGO, ABUS, SANA, CDXC, SION, and KALVShould you be buying Ocugen stock or one of its competitors? The main competitors of Ocugen include LENZ Therapeutics (LENZ), Maravai LifeSciences (MRVI), Dianthus Therapeutics (DNTH), CorMedix (CRMD), Organogenesis (ORGO), Arbutus Biopharma (ABUS), Sana Biotechnology (SANA), ChromaDex (CDXC), Sionna Therapeutics (SION), and KalVista Pharmaceuticals (KALV). These companies are all part of the "pharmaceutical products" industry. Ocugen vs. LENZ Therapeutics Maravai LifeSciences Dianthus Therapeutics CorMedix Organogenesis Arbutus Biopharma Sana Biotechnology ChromaDex Sionna Therapeutics KalVista Pharmaceuticals Ocugen (NASDAQ:OCGN) and LENZ Therapeutics (NASDAQ:LENZ) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership, community ranking, earnings and media sentiment. Which has higher earnings and valuation, OCGN or LENZ? Ocugen has higher revenue and earnings than LENZ Therapeutics. LENZ Therapeutics is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOcugen$4.06M51.47-$63.08M-$0.19-3.76LENZ TherapeuticsN/AN/A-$124.65M-$4.77-5.54 Does the MarketBeat Community prefer OCGN or LENZ? Ocugen received 101 more outperform votes than LENZ Therapeutics when rated by MarketBeat users. However, 100.00% of users gave LENZ Therapeutics an outperform vote while only 71.07% of users gave Ocugen an outperform vote. CompanyUnderperformOutperformOcugenOutperform Votes11371.07% Underperform Votes4628.93% LENZ TherapeuticsOutperform Votes12100.00% Underperform VotesNo Votes Do analysts recommend OCGN or LENZ? Ocugen presently has a consensus price target of $6.33, indicating a potential upside of 786.15%. LENZ Therapeutics has a consensus price target of $41.67, indicating a potential upside of 57.65%. Given Ocugen's higher probable upside, analysts clearly believe Ocugen is more favorable than LENZ Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ocugen 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00LENZ Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 Which has more risk and volatility, OCGN or LENZ? Ocugen has a beta of 3.88, meaning that its stock price is 288% more volatile than the S&P 500. Comparatively, LENZ Therapeutics has a beta of 0.58, meaning that its stock price is 42% less volatile than the S&P 500. Do institutionals & insiders have more ownership in OCGN or LENZ? 10.3% of Ocugen shares are owned by institutional investors. Comparatively, 54.3% of LENZ Therapeutics shares are owned by institutional investors. 4.3% of Ocugen shares are owned by insiders. Comparatively, 38.4% of LENZ Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Is OCGN or LENZ more profitable? LENZ Therapeutics has a net margin of 0.00% compared to Ocugen's net margin of -532.51%. LENZ Therapeutics' return on equity of -58.48% beat Ocugen's return on equity.Company Net Margins Return on Equity Return on Assets Ocugen-532.51% -154.75% -90.79% LENZ Therapeutics N/A -58.48%-55.50% Does the media refer more to OCGN or LENZ? In the previous week, LENZ Therapeutics had 39 more articles in the media than Ocugen. MarketBeat recorded 41 mentions for LENZ Therapeutics and 2 mentions for Ocugen. Ocugen's average media sentiment score of 0.62 beat LENZ Therapeutics' score of 0.57 indicating that Ocugen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ocugen 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive LENZ Therapeutics 8 Very Positive mention(s) 3 Positive mention(s) 14 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive SummaryLENZ Therapeutics beats Ocugen on 10 of the 18 factors compared between the two stocks. Remove Ads Get Ocugen News Delivered to You Automatically Sign up to receive the latest news and ratings for OCGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OCGN vs. The Competition Export to ExcelMetricOcugenBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$208.70M$3.03B$5.68B$8.30BDividend YieldN/A1.54%4.55%4.02%P/E Ratio-3.9729.9524.5519.25Price / Sales51.47447.85395.7294.10Price / CashN/A168.6838.1634.64Price / Book4.474.227.064.46Net Income-$63.08M-$71.72M$3.19B$247.07M7 Day Performance38.43%-2.22%1.49%3.05%1 Month Performance18.09%-9.53%5.87%-2.85%1 Year Performance-60.95%-22.57%14.94%4.63% Ocugen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OCGNOcugen1.0105 of 5 stars$0.71+12.1%$6.33+786.2%-60.9%$208.70M$4.06M-3.9780Gap UpLENZLENZ Therapeutics2.1712 of 5 stars$24.31-4.5%$35.40+45.6%+61.9%$668.55MN/A0.00110Earnings ReportAnalyst RevisionMRVIMaravai LifeSciences4.7562 of 5 stars$2.62+6.7%$9.28+254.9%-72.9%$664.15M$276.92M-1.60610Analyst ForecastGap UpDNTHDianthus Therapeutics1.3268 of 5 stars$22.43+5.2%$52.14+132.5%-41.0%$663.86M$6.24M-8.9780High Trading VolumeCRMDCorMedix2.0388 of 5 stars$10.57+1.0%$16.00+51.3%+79.9%$641.96M$12.26M-13.0630Earnings ReportAnalyst ForecastOptions VolumeNews CoverageGap DownORGOOrganogenesis3.1113 of 5 stars$4.99-0.5%$5.50+10.3%+99.2%$634.77M$482.04M-83.42950ABUSArbutus Biopharma2.2125 of 5 stars$3.31+0.2%$5.50+66.4%+35.3%$626.27M$6.74M-7.6990Upcoming EarningsSANASana Biotechnology3.1032 of 5 stars$2.79-4.9%$12.25+339.9%-76.3%$623.59MN/A-2.00380News CoverageCDXCChromaDex4.3939 of 5 stars$7.99+1.9%$9.03+13.1%N/A$620.91M$99.60M799.40120SIONSionna TherapeuticsN/A$14.60-2.5%$38.50+163.7%N/A$620.81MN/A0.0035Earnings ReportKALVKalVista Pharmaceuticals4.4803 of 5 stars$12.52-0.7%$23.80+90.2%+12.3%$618.47MN/A-3.44100 Remove Ads Related Companies and Tools Related Companies LENZ Therapeutics Alternatives Maravai LifeSciences Alternatives Dianthus Therapeutics Alternatives CorMedix Alternatives Organogenesis Alternatives Arbutus Biopharma Alternatives Sana Biotechnology Alternatives ChromaDex Alternatives Sionna Therapeutics Alternatives KalVista Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OCGN) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy sharehold...Golden Portfolio | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredThis Crypto Is Set to Explode in FebruaryBryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ocugen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ocugen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
